A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

To join this study, you need to be at least 18 years old and fully understand what the study involves before agreeing to take part. It's also important that your main organs, like your kidneys and liver, are working properly, and your blood clotting is normal. \n\nIf you are a woman who could become pregnant, you'll need to use a very effective method of contraception throughout the study and for 12 months after your last dose of DR-01. Men taking part will also need to use an effective method of contraception. \n\nFor those with LGLL, you must have tried at least one other treatment before. If you have a cytotoxic lymphoma, you must have also tried at least one past treatment. Additionally, for people with cytotoxic lymphomas, the study will need either a tissue sample taken after your last treatment, or you must be willing to have a new biopsy (a small tissue sample taken for examination). Your diagnosis must also be officially confirmed by a specialist.

If you decide to take part in this study, you'll be given the study medicine, DR-01. The amount of DR-01 you receive will be carefully monitored, especially in the early stages of the study, to find the safest and most effective dose. \n\nThroughout your time in the study, you'll have regular visits to the clinic. During these visits, the research team will perform various tests and checks. These will likely include blood tests, physical examinations, and scans (like CT or PET scans) to see how your body is reacting to the medicine and how your cancer might be changing. You might also have additional biopsies if required for follow-up. \n\nThe research team will provide specific details on how often these visits will be, what each visit will involve, and how long you are expected to be in the study overall. You'll also have a follow-up period after your last dose of DR-01 to monitor your health.